MX2024010078A - Compuestos de pirazolilo como activadores del canal de potasio dependientes de voltaje 7 (kv7). - Google Patents
Compuestos de pirazolilo como activadores del canal de potasio dependientes de voltaje 7 (kv7).Info
- Publication number
- MX2024010078A MX2024010078A MX2024010078A MX2024010078A MX2024010078A MX 2024010078 A MX2024010078 A MX 2024010078A MX 2024010078 A MX2024010078 A MX 2024010078A MX 2024010078 A MX2024010078 A MX 2024010078A MX 2024010078 A MX2024010078 A MX 2024010078A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- activators
- voltage
- potassium channel
- dependent potassium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263313208P | 2022-02-23 | 2022-02-23 | |
| PCT/US2023/063111 WO2023164536A1 (en) | 2022-02-23 | 2023-02-23 | Pyrazolyl compounds as kv7 channel activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010078A true MX2024010078A (es) | 2024-08-27 |
Family
ID=87766731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010078A MX2024010078A (es) | 2022-02-23 | 2023-02-23 | Compuestos de pirazolilo como activadores del canal de potasio dependientes de voltaje 7 (kv7). |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20250171429A1 (enExample) |
| EP (1) | EP4482489A4 (enExample) |
| JP (1) | JP2025507542A (enExample) |
| KR (1) | KR20240151835A (enExample) |
| CN (1) | CN118695860A (enExample) |
| AU (1) | AU2023225024A1 (enExample) |
| CA (1) | CA3244500A1 (enExample) |
| IL (1) | IL314554A (enExample) |
| MX (1) | MX2024010078A (enExample) |
| WO (1) | WO2023164536A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023164537A1 (en) * | 2022-02-23 | 2023-08-31 | Biohaven Therapeutics Ltd. | Pyrazolyl compounds as kv7 channel activators |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1441724E (pt) * | 2001-09-27 | 2007-10-15 | Serono Lab | Métodos para aumentar os níveis endógenos de testosterona |
| AU2002363250A1 (en) * | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| WO2003039529A1 (en) * | 2001-11-07 | 2003-05-15 | 4Sc A.G. | Selective antibacterial agents |
| ATE410161T1 (de) * | 2003-05-02 | 2008-10-15 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
| CA2525245C (en) * | 2003-06-27 | 2010-10-19 | Pfizer Products Inc. | Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| WO2005048953A2 (en) * | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Amide derivatives as kinase modulators |
| ES2317079T3 (es) * | 2003-12-24 | 2009-04-16 | Astrazeneca Ab | Pirimidinas con actividad tie2 (tek). |
| CA2592118C (en) * | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
| DOP2006000233A (es) * | 2005-10-28 | 2007-06-15 | Lilly Co Eli | Inhibidores de cinasa |
| PL2510925T3 (pl) * | 2006-02-15 | 2017-03-31 | Dendreon Pharmaceuticals, Inc. | Drobnocząsteczkowe modulatory aktywności trp-p8 |
| ES2351274T3 (es) * | 2007-06-06 | 2011-02-02 | Torrent Pharmaceuticals Ltd | Nuevos compuestos. |
| US8486987B2 (en) * | 2007-11-16 | 2013-07-16 | University Of Medicine And Dentistry Of New Jersey | Mechanism-based small-molecule parasite inhibitors |
| AU2009226136B2 (en) * | 2008-03-17 | 2013-08-15 | Ambit Biosciences Corporation | Quinazoline derivatives as RAF kinase modulators and methods of use thereof |
| CA2724413C (en) * | 2008-05-15 | 2016-10-18 | Duke University | Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof |
| US9315449B2 (en) * | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| CN103619171B (zh) * | 2010-11-03 | 2015-11-25 | 陶氏益农公司 | 杀虫组合物和与其相关的方法 |
| US9227976B2 (en) * | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| CA2891334C (en) * | 2012-11-13 | 2021-10-19 | Array Biopharma Inc. | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain |
| US9822118B2 (en) * | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9067894B1 (en) * | 2013-03-07 | 2015-06-30 | Vanderbilt University | Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest |
| EP3558992A4 (en) * | 2016-12-15 | 2020-12-02 | ONO Pharmaceutical Co., Ltd. | TREK CHANNEL ACTIVATOR (K + CHANNELS ASSOCIATED WITH TWIK) |
| PH12021553058A1 (en) * | 2019-06-06 | 2022-07-25 | Hutchison Medipharma Ltd | Tricyclic compounds and their use |
-
2023
- 2023-02-23 CN CN202380021419.2A patent/CN118695860A/zh active Pending
- 2023-02-23 IL IL314554A patent/IL314554A/en unknown
- 2023-02-23 US US18/839,858 patent/US20250171429A1/en active Pending
- 2023-02-23 MX MX2024010078A patent/MX2024010078A/es unknown
- 2023-02-23 WO PCT/US2023/063111 patent/WO2023164536A1/en not_active Ceased
- 2023-02-23 KR KR1020247031504A patent/KR20240151835A/ko active Pending
- 2023-02-23 CA CA3244500A patent/CA3244500A1/en active Pending
- 2023-02-23 AU AU2023225024A patent/AU2023225024A1/en active Pending
- 2023-02-23 EP EP23760908.6A patent/EP4482489A4/en active Pending
- 2023-02-23 JP JP2024547296A patent/JP2025507542A/ja active Pending
-
2025
- 2025-04-01 US US19/097,371 patent/US20250230152A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023225024A1 (en) | 2024-08-29 |
| US20250230152A1 (en) | 2025-07-17 |
| JP2025507542A (ja) | 2025-03-21 |
| CA3244500A1 (en) | 2023-08-31 |
| US20250171429A1 (en) | 2025-05-29 |
| WO2023164536A1 (en) | 2023-08-31 |
| EP4482489A1 (en) | 2025-01-01 |
| IL314554A (en) | 2024-09-01 |
| CN118695860A (zh) | 2024-09-24 |
| KR20240151835A (ko) | 2024-10-18 |
| EP4482489A4 (en) | 2026-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202308070B (en) | Kv7 channel activators compositions and methods of use | |
| JOP20220130B1 (ar) | مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم | |
| PH12023552741A1 (en) | Psilocybin Compositions, Methods Of Making And Methods Of Using The Same | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2020012602A (es) | Composiciones bacterianas dise?adas y usos de las mismas. | |
| PH12021551792A1 (en) | Bi-ligand drug conjugate and use thereof | |
| MX385898B (es) | Moleculas de fusion derivadas de la toxina colix para suministro oral de una carga biologicamente activa. | |
| MX2018005256A (es) | Formulaciones inyectables de toxina botulinica y metodos de uso de las mismas que tienen efecto terapautico o cosmetico de larga duracion. | |
| BR112021019931A2 (pt) | Parasiticidas isoxazolina sistêmicos para tratamento ou profilaxia de doença transmitida por vetor e viral | |
| EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| MX2024015063A (es) | Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades | |
| WO2018140792A3 (en) | Neurotrophin mutants for treating hearing loss and other otic disorders | |
| MX2025002265A (es) | Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares | |
| IL307992A (en) | Parasitic formulations containing isoxazoline and methods for treating blepharitis | |
| JOP20230089A1 (ar) | مثبطات إنترليوكين-17 | |
| MX2025014320A (es) | Compuestos nitrogenados aromaticos, metodos de preparacion y usos medicinales | |
| MX2026000796A (es) | Composiciones de administracion mejorada de epinefrina y profarmacos | |
| MX2024010081A (es) | Compuestos de pirazolilo como activadores del canal de potasio dependientes de voltaje 7 (kv7). | |
| CR20250293A (es) | Formulaciones de enzima hialuronidasa para la administración de alto volumen | |
| MX2022003051A (es) | Formulaciones para la administracion de farmacos. | |
| MX2024010568A (es) | Compuestos terapeuticos, formulaciones y uso de estos. | |
| MX2025004084A (es) | Uso de dosis mas altas de formulaciones de huperzina de liberacion modificada | |
| WO2025137652A3 (en) | Compositions comprising radiprodil and the use of radiprodil in the treatment of epileptic or neurobehavioral disorders | |
| BR112022003126A2 (pt) | Conjugado terapêutico | |
| MX2021008188A (es) | Compuestos de anandamida. |